The nature of the “oat celled” sarcoma of the mediastinum. J. Pathol. Bacteriol. 29, 241–244 (1926). This study represents the identification of SCLC as a lung cancer. Google Scholar Azzopardi, J. G. Oat-cell carcinoma of the bronchus. J. Pathol. Bacteriol. 78, 513–519 (1959)...
following treatment for neuroblastoma, the role of chemotherapy, whole brain radiotherapy for multiple metastases to the brain from primary cancers, and synovial sarcoma metastasized to the brain; brain metastases from non-small cell lung carcinoma; and brain metastases from small cell lung carcinoma. ...
Small-cell lung cancer: Therapeutic challengesMalignant fibrous histiocytoma (MFH) is the most common soft tissue sarcoma in adults. Its appearance as a primary lung tumor is extremely rare. The cell origin of MFH r...
Kirsten Rat Sarcoma viral oncogene homolog (KRAS) gene is a gene that produces a protein that functions in the cell signaling systems that regulate cell division, maturation, and growth. It is the most mutated oncogene in human cancers, which hinders the development of effective drugs against KRA...
Although small cell lung cancer (SCLC) is treated as a homogeneous disease, biopsies and preclinical models reveal heterogeneity in transcriptomes and morphology. SCLC subtypes were recently defined by neuroendocrine transcription factor (NETF) expressio
网络释义 1. 小细胞肉瘤 small-英汉词典-英中字典-速译通... ... Small cell osteosarcoma [医]小细胞性骨肉瘤Small cell sarcoma[医]小细胞肉瘤... www.fastdict.net|基于 1 个网页
Less often, SIADH affects people with non-small-cell lung cancer or cancers like these: Ewing's sarcoma Lymphoma Mesothelioma Squamous cell carcinomaof the head and neck Cancer of the thymus, called thymoma What Symptoms Does SIADH Cause?
cationic liposome, DDS, drug delivery system, Tf, transferrin, TfR, Tf receptor, VEC, vascular endothelial cell Department of Orthopaedics, University of Melbourne, St. Vincent's Hospital Melbourne, Australia Bone and Soft Tissue Sarcoma Service, Peter MacCallum Cancer Institute, Melbourne, Australia ...
Lung cancer is the primary contributor to cancer-related deaths globally, and non-small cell lung cancer (NSCLC) constitutes around 85% of all lung cancer cases. Recently, the emergence of targeted therapy and immunotherapy revolutionized the treatment o
lung cancer, sarcoma, including osteogenic sarcoma, mesothelioma, sporadic nonfamilial tumors, lymphoma, and others including hematologic cancers such chronic myelogenous leukemia. Precancerous conditions, where cells exhibit high amounts of HDM-2 in the plasma membrane, are also included as treatable ...